Search clinical trials for: IDP-122 Vehicle Lotion

Total 3194 results

Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

Atopic Dermatitis

United States
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Atopic Dermatitis

United States
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Valeant Pharmaceuticals

Unknown

A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Bausch Health Americas, Inc.

Completed

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Acne

United States
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.

Completed

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States, Canada
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
Bausch Health Americas, Inc.

Recruiting

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Psoriasis

United States, Panama
Valeant Pharmaceuticals

Unknown

Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris

Acne Vulgaris
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis

Psoriasis

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

Acne

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Dow Pharmaceutical Sciences

Completed

The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Onychomycosis

United States, Canada
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

Onychomycosis

United States, Canada, Japan
Dow Pharmaceutical Sciences

Completed

A Clinical Study Evaluating the Safety and Efficacy of IDP-115 in Patients With Rosacea

Rosacea

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

Acne Vulgaris

United States, Belgium, Canada
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Acne

United States
Dow Pharmaceutical Sciences

Completed

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis

Onychomycosis

Mexico
Bausch Health Americas, Inc.

Completed

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

Psoriasis

United States
Bausch Health Americas, Inc.

Completed

Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel

Acne

United States
Sienna Biopharmaceuticals

Completed

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

Pruritus | Psoriasis Vulgaris

United States
PreCision Dermatology, Inc.

Completed

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Bausch Health Americas, Inc.

Completed

Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel

Acne Vulgaris

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With DED (STRIDE 3)

Kerato Conjunctivitis Sicca

United States
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (Hawaii-1)

Ocular Infections, Irritations and Inflammations

United States
Warner Chilcott

Terminated

Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction

Erectile Dysfunction

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

MZL

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (ICC)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Advanced Solid Tumor

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study of ICP-022 in Patients With R/R DLBCL (DLBCL)

Diffuse Large B Cell Lymphoma

China

3

Subscribe